onr:"swepub:oai:DiVA.org:uu-54712"
Search: onr:"swepub:oai:DiVA.org:uu-54712" > Polymorphisms of NA...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Wadelius, MiaUppsala universitet,Klinisk farmakogenomik och osteoporos (author)
Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis
- Article/chapterEnglish2000
Publisher, publication year, extent ...
- 2000
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:uu-54712
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-54712URI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Agranulocytosis is a rare, but serious adverse reaction to sulphasalazine. The polymorphic enzyme N-acetyltransferase 2 (NAT2) plays an important role in the metabolism of sulphasalazine. This study was conducted to analyse whether the risk of sulphasalazine-induced agranulocytosis is increased in slow acetylators. Patients were treated for inflammatory disease, mostly joint disease, with a mean dose of 2 g sulphasalazine daily. Thirty-nine patients reacted with agranulocytosis, while 75 patients had been treated for a minimum of 3 months without haematological side-effects. A population-based control panel of 448 individuals was used for comparison. All subjects were genotyped for NAT2 by polymerase chain reaction followed by restriction enzyme digestion. The six most common allelic variants were analysed: NAT2*4, NAT2*5A, NAT2*5B, NAT2*5C, NAT2*6 and NAT2*7. The proportion of slow acetylators was significantly higher in patients with sulphasalazine-induced agranulocytosis (69%) and population-based controls (64%) compared to patients who tolerated sulphasalazine (45%); odds ratio 2.71 [95% confidence interval (CI) 1.20; 6.15], P = 0.015, and odds ratio 2.17 (95% CI 1.32; 3.56), P = 0.002, respectively. Patients who developed agranulocytosis did not differ from population-based control subjects in the frequency of slow acetylators; odds ratio 1.25 (95% CI 0.62; 2.53), P = 0.535. The risk of agranulocytosis did not appear to be increased in slow acetylators, provided that the difference compared with sulphasalazine-treated control subjects was not due to a predominance of fast acetylators among patients with inflammatory joint disease. Instead, selection bias was suspected since more slow acetylators may have discontinued sulphasalazine therapy because of drug-intolerance.
Subject headings and genre
- sulfasalazine
- agranulocytosis
- NAT2
- pharmacogenetics
- MEDICINE
- MEDICIN
Added entries (persons, corporate bodies, meetings, titles ...)
- Stjernberg, ElisabethUppsala universitet,Klinisk farmakologi (author)
- Wiholm, Bengt-Erik (author)
- Rane, AndersUppsala universitet,Institutionen för medicinska vetenskaper,Klinisk farmakologi, A Rane (author)
- Uppsala universitetKlinisk farmakogenomik och osteoporos (creator_code:org_t)
Related titles
- In:Pharmacogenetics10:1, s. 35-410960-314X1473-561X
Internet link
Find in a library
- Pharmacogenetics (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Wadelius, Mia
- Stjernberg, Elis ...
- Wiholm, Bengt-Er ...
- Rane, Anders
- Articles in the publication
- Pharmacogenetics
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
